Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
Status:
Unknown status
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir
in patients with Hepatitis C (HCV) genotype2,3,6. Efficacy was assessed by the rate of
sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12).